Corporate results:

  • Philips raises its outlook and increases its third-quarter profit.
  • Vistry lowers its annual profit forecast and plans to cut 200 jobs.
  • Volkswagen warns that its operating margin will only be stable this year.

In other news:

  • Foxconn (Hon Hai Precision), Apple's main supplier, is under investigation in China.
  • Roche acquires Telavant, Roivant's bowel disease drug, for $7.1 billion.
  • Compagnie Financière Richemont receives the green light from the EU for the sale of Yoox Net-A-Porter.
  • Unicredit merges its activities in Romania with Alpha Services and signs a partnership in Greece.
  • Eli Lilly and Novo Nordisk plan to test weight-loss drugs in younger patients.
  • Eckert & Ziegler plans to spin off its subsidiary Pentixapharm.
  • Indivior to pay $385m to settle Suboxone monopoly lawsuit.
  • GSK and Hansoh Pharma sign exclusive licensing agreement for HS-20089.
  • SGS sells activities in North America.
  • Chevron announced on Monday the acquisition of Hess in an all-stock transaction worth $53 billion. Chevron is offering $171 for each Hess share.
  • Apple - Chinese e-commerce platforms are offering major promotions on Apple's iPhone 15, which analysts say is selling less well than the previous iPhone in the country.
  • Alphabet - Japan's competition authority said it had opened an investigation into search engine Google for possible violation of anti-monopoly rules.
  • Roche announced that it had acquired the Telavant treatment for inflammatory bowel disease for an initial sum of $7.1 billion from the Roivant Holdings and Pfizer groups.
  • Merck - Chinese drugmaker Sichuan Kelun Pharmaceutical announced that Merck had abandoned the joint development of two cancer drug candidates that have yet to enter clinical trials.
  • Farfetch - European authorities have approved Farfetch's purchase of a stake in its rival Yoox Net-A-Porter, owned by Richemont.
  • P10 - A former long-time Goldman Sachs executive, Luke Sarsfield, is to take over as CEO of the asset management company, the Wall Street Journal reported on Sunday. 
  • Textainer - The container leasing company said on Sunday that US infrastructure investor Stonepeak would buy it for around $2.1 billion.
  • Biomarin Pharmaceutical - The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of a Biomarin Pharmaceutical treatment to treat children under 5 suffering from the most common form of short-limbed dwarfism.
    Today's main earnings reports: Cadence Design, Unicredit, Nidec, Sandvik, Philips, Logitech...The full earnings calendar is here.